Intellia Therapeutics vs Wave Life Sciences
NTLA and WVE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NTLA and WVE compare
Intellia Therapeutics is the larger company, worth 2.2 times as much as Wave Life Sciences ($1.4B against $617M).
Wave Life Sciences keeps more of each dollar of sales as profit, with a net margin of −297% compared with −806% at Intellia Therapeutics.
Wave Life Sciences scores higher on the StockData Score (10 against 3 for Intellia Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NTLA | WVE |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $617M |
| Share price | $9.70 | $3.13 |
| Change, 1 year | 2.2% | −55.0% |
| Change, 5 years | −92.5% | −27.4% |
| Beta (5Y) | 2.08 | 1.30 |
| Employees | 377 | 317 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 25.7× | 8.7× (better) |
| P/B | 2.2× | 1.5× (better) |
| FCF yield | −26.3% (better) | −33.8% |
| Fair value | $7.77 | $5.15 |
| Margin of safety | −24.9% | 39.2% (better) |
| Growth | ||
| Revenue growth (TTM) | −8.1% | – |
| Revenue growth, 5Y average | 3.1% | 16.3% (better) |
| Profitability | ||
| Operating margin | −821% | −321% (better) |
| Net margin | −806% | −297% (better) |
| FCF margin | −677% | −294% (better) |
| Return on equity | −62.6% (better) | −80.0% |
| Return on invested capital | −152% | – |
| Financial health | ||
| Debt / equity | 0.12 (better) | 0.00 |
| Current ratio | 6.31 | 8.38 (better) |
| Altman Z-score | −2.68 | −0.98 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 92.6% |
| Held by insiders | 2.0% | 23.1% |
| Insider net buying, 12 months | −$869K | $66.5M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 32.3% | 13.6% |
Go deeper
- NTLA stock overview
- NTLA income statement
- NTLA valuation and score
- WVE stock overview
- WVE income statement
- WVE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.